Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Apr 11, 2014 3:21pm

152 Views

Post# 22441475

RE:G1945V... activists launch Operation Monsanto Stock Plunge

Hi kelsee.

Doesn't worry me with regards to RVX and Zenith. At the end of the day any company is going to stand alone based on it's performance.

That being said the performance at RVX I guess will be judged by the replication of the MACE results which seems to have good odds based on the p values (IMO) in the post hoc analysis.

Let's hope...but Don better get moving.
Cheers
Toinv :)

Bullboard Posts

How one company is disrupting PoC testing